Management of endocrine surgical disorders during COVID-19 pandemic: expert opinion for non-surgical options.
Consensus
Endocrine disease
Expert opinion
Pandemic
Qualtrics
Survey
Journal
Updates in surgery
ISSN: 2038-3312
Titre abrégé: Updates Surg
Pays: Italy
ID NLM: 101539818
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
10
10
2020
accepted:
12
01
2021
pubmed:
12
4
2021
medline:
12
2
2022
entrez:
11
4
2021
Statut:
ppublish
Résumé
The COVID-19 pandemic brought unprecedented conditions for overall health care systems by restricting resources for non-COVID-19 patients. As the burden of the disease escalates, routine elective surgeries are being cancelled. The aim of this paper was to provide a guideline for management of endocrine surgical disorders during a pandemic. We used Delphi method with a nine-scale Likert scale on two rounds of voting involving 64 experienced eminent surgeons and endocrinologists who had the necessary experience to provide insight on endocrine disorder management. All voting was done by email using a standard questionnaire. Overall, 37 recommendations were voted on. In two rounds, all recommendations reached an agreement and were either endorsed or rejected. Endorsed statements include dietary change in primary hyperparathyroidism, Cinacalcet treatment in secondary hyperparathyroidism, alpha-blocker administration for pheochromocytoma, methimazole ± β-blocker combination for Graves' disease, and follow-up for fine-needle aspiration results of thyroid nodules indicated as Bethesda 3-4 cytological results and papillary microcarcinoma. This survey summarizes expert opinion for the management of endocrine surgical conditions during unprecedented times when access to surgical treatment is severely disrupted. The statements are not applicable in circumstances in which surgical treatment is possible.
Identifiants
pubmed: 33840069
doi: 10.1007/s13304-021-00979-8
pii: 10.1007/s13304-021-00979-8
pmc: PMC8036242
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
325-335Informations de copyright
© 2021. Italian Society of Surgery (SIC).
Références
Zarzaur BL, Stahl CC, Greenberg JA, Savage SA, Minter RM (2020) Blueprint for restructuring a department of surgery in concert with the health care system during a pandemic: The University of Wisconsin experience. JAMA Surg. 155(7):628–635
doi: 10.1001/jamasurg.2020.1386
Ayyaz M, Butt UI, Umar M, Khan WH, Kashif MR, Hyidar Z (2020) Effect of COVID-19 on the working of a tertiary care hospital. J Coll Physicians Surg Pak 30(10):164–167
doi: 10.29271/jcpsp.2020.supp2.S164
McBride KE, Brown KGM, Fisher OM, Steffens D, Yeo DA, Koh CE (2020) Impact of the COVID-19 pandemic on surgical services: early experiences at a nominated COVID-19 centre. ANZ J Surg 90:663–665
doi: 10.1111/ans.15900
Besnier E, Tuech JJ, Schwarz L (2020) We asked the experts: Covid-19 outbreak: is there still a place for scheduled surgery? “Reflection from pathophysiological data.” World J Surg 44:1695–1698
doi: 10.1007/s00268-020-05501-6
Al-Omar K, Bakkar S, Khasawneh L, Donatini G, Miccoli P (2020) Resuming elective surgery in the time of COVID-19: a safe and comprehensive strategy. Updates Surg 72(2):291–295
doi: 10.1007/s13304-020-00822-6
Tuech JJ, Gangloff A, Di Fiore F, Michel P, Brigand C, Slim K et al (2020) Strategy for the practice of digestive and oncological surgery during the COVID-19 epidemic. J Visc 157:7–12
doi: 10.1016/j.jviscsurg.2020.03.008
Iacobucci G (2020) COVID-19: all non-urgent elective surgery is suspended for at least 3 months in England. BMJ 368:m1106
doi: 10.1136/bmj.m1106
Baud G, Brunaud L, Lifante JC, Tresallet C, Sebag F, Bizard JP et al (2020) Endocrine surgery during and after the COVID-19 epidemic: guidelines from AFCE. J Chir Visc 157:44–51
Cope O (1966) The study of hyperparathyroidism at the Massachusetts General Hospital. N Engl J Med 274:1174–1182
doi: 10.1056/NEJM196605262742105
Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP (1999) A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 341:1249–1255
doi: 10.1056/NEJM199910213411701
Bilezikian JP (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 99:3561–3569
doi: 10.1210/jc.2014-1413
Wilhelm SM (2016) The American Association of Endocrine Surgeons Guidelines for definitive management of primary hyperparathyroidism. JAMA Surg 151:959–968
doi: 10.1001/jamasurg.2016.2310
Marcocci C, Bollerslev J, Khan AA, Shoback DM (2014) Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. J Clin Endocrinol Metab 99:3607–3618
doi: 10.1210/jc.2014-1417
Cannon J, Lew JI, Solorzano CC (2010) Parathyroidectomy for hypercalcemic crisis: 40 years’ experience and long-term outcomes. Surgery 148:807–813
doi: 10.1016/j.surg.2010.07.041
Roy R, Lee JA (2011) Calciphylaxis due to hyperparathyroidism. Endocr Pract 17:54–56
doi: 10.4158/EP10349.RA
Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D (2005) Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90:135–141
doi: 10.1210/jc.2004-0842
Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208–2218
doi: 10.1097/01.ASN.0000133041.27682.A2
Schneider R, Slater EP, Karakas E, Bartsch DK, Schlosser K (2012) Initial parathyroid surgery in 606 patients with renal hyperparathyroidism. World J Surg 36:318–326
doi: 10.1007/s00268-011-1392-0
Ikizler TA, Kliger AS (2020) Minimising the risk of COVID-19 among patients on dialysis. Nat Rev Nephrol 16:311–313
doi: 10.1038/s41581-020-0280-y
Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG et al (2012) EVOLVE Trial Investigators: effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367:2482–2494
doi: 10.1056/NEJMoa1205624
London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H (2003) Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18:1731–1740
doi: 10.1093/ndt/gfg414
Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D et al (1999) A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33:694–701
doi: 10.1016/S0272-6386(99)70221-0
Drueke TB, Ritz E (2009) Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives. Clin J Am Soc Nephrol 4:234–241
doi: 10.2215/CJN.04520908
Lenders JW, Duh QY, Eisenhofer G, Roqueplo APG, Grebe SKG, Murad MH et al (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:1915–1942
doi: 10.1210/jc.2014-1498
Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM et al (2014) Adrenocortical carcinoma. Endocr Rev 35:282–326
doi: 10.1210/er.2013-1029
Fassnacht M, Libé R, Kroiss M, Allolio B (2011) Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol 7:323–335
doi: 10.1038/nrendo.2010.235
Berruti A, Terzolo M, Sperone P, Pia A, Casa SD, Gross DJ et al (2005) Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12:657–666
doi: 10.1677/erc.1.01025
Khan TS, Imam H, Juhlin C, Skogseid B, Gröndal S, Tibblin S et al (2000) Streptozocin and o, p’DDD in the treatment of adrenocortical cancer patients: longterm survival in its adjuvant use. Ann Oncol 11:1281–1287
doi: 10.1023/A:1008377915129
Gaujoux S, Mihai R (2017) European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma. Br J Surg 104:358–376
doi: 10.1002/bjs.10414
Smith TJ, Hegedus L (2016) Graves’ disease. N Engl J Med 375:1552–1565
doi: 10.1056/NEJMra1510030
Bartalena L (2013) Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol 9:724–734
doi: 10.1038/nrendo.2013.193
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE et al (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1–133
doi: 10.1089/thy.2015.0020
Bakkar S, Al-Omar K, Aljarrah Q, Al-Dabbas M, Al-Dabbas N, Samara S et al (2020) Impact of COVID-19 on thyroid cancer surgery and adjunct therapy. Updates Surg 72(3):867–869
doi: 10.1007/s13304-020-00833-3
Ito Y, Miyauchi A, Oda H (2018) Low-risk papillary microcarcinoma of the thyroid: a review of active surveillance trials. Eur J Surg Oncol 44:307–315
doi: 10.1016/j.ejso.2017.03.004
Lim CY, Yun JS, Lee J, Nam KH, Chung WY, Park CS (2007) Percutaneous ethanol injection therapy for locally recurrent papillary thyroid carcinoma. Thyroid 17:347–350
doi: 10.1089/thy.2006.0251
Dupuy DE, Monchik JM, Decrea C, Pisharodi L (2001) Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy. Surgery 130:971–977
doi: 10.1067/msy.2001.118708
Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF et al (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25:567–610
doi: 10.1089/thy.2014.0335
Powell C (2003) The Delphi technique: myths and realities. J Adv Nurs 41:376–382
doi: 10.1046/j.1365-2648.2003.02537.x